Company intelligence / Profile preview

Hoechst Marion Roussel

Paris, Île-de-France, France

Ownership: Private
Employees: ~16551
Development stage: Other

Overview

Hoechst Marion Roussel (including Roussel Uclaf) launched several successful commercial products in antibiotics, endocrinology, and women’s health, notably mifepristone (RU-486) used for medical abortion; other key products included Claforan (third-generation cephalosporin) and Insuman (human insulin); their pipeline was commercialized or handed off to successor companies.

Therapeutic areas: CardiovascularEndocrinologyWomen's HealthInfectious DiseasesNeurologyOncology
Modalities: Small moleculeAntibioticHormoneBiologic
Industry: Pharma

Partnerships

Hoechst AGRhône-PoulencPopulation Council (RU-486 US distribution)Nobel-Bozel (joint chemical operations)Nobel-Hoechst Chimie (chemicals)Hoechst Schering AgrEvo (agrochemicals)Aventis (post-merger)

Beyond the preview

Go deeper on Hoechst Marion Roussel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hoechst Marion Roussel.

Explore the full profile